- 全部删除
 
您的购物车当前为空
CD161 is a potent, selective, and orally bioavailable BET bromodomain inhibitor (IC50s: 28.2 nM and 7.2 nM for BRD4 BD1 and BRD4 BD2) with good anticancer activity.

CD161 is a potent, selective, and orally bioavailable BET bromodomain inhibitor (IC50s: 28.2 nM and 7.2 nM for BRD4 BD1 and BRD4 BD2) with good anticancer activity.
| 规格 | 价格 | 库存 | 数量 | 
|---|---|---|---|
| 25 mg | ¥ 11,700  | 6-8周 | |
| 50 mg | ¥ 15,300  | 6-8周 | |
| 100 mg | ¥ 19,500  | 6-8周 | 
CD161 相关产品
| 产品描述 | CD161 is a potent, selective, and orally bioavailable BET bromodomain inhibitor (IC50s: 28.2 nM and 7.2 nM for BRD4 BD1 and BRD4 BD2) with good anticancer activity.  | 
| 靶点活性 |  BRD4 BD2:7.2 nM, BRD4 BD1:28.2 nM  | 
| 体外活性 | CD161 (NKR-P1A) (30-3000 nM; 1 hour) is very effective in inducing rapid down-regulation of c-Myc at as early as the 1 h time point and in a dose-dependent manner. CD161 has Kis of 8.2 nM and 1.4 nM for BRD4 BD1 and BRD4 BD2, respectively.  | 
| 体内活性 | CD161 (5 mg/kg (iv), 25 mg/kg (po); 0-24 hours) has the t1/2 of 2.4 hours (iv) and 2.9 hours (po) for rat; the Cmax of 7333 ng/mL (po) for rat. CD161 (po; 20, 40 mg/kg/day; 45 days) achieves essentially complete tumor growth inhibition. The t1/2 of mice is 0.5 hours (iv) and 1.60 hours (po); the Cmax of mice is 983.1 ng/mL (po).  | 
| 别名 | NKR-P1A | 
| 分子量 | 435.48 | 
| 分子式 | C26H21N5O2 | 
| CAS No. | 1627716-22-6 | 
| 密度 | no data available | 
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | 
评论内容